Search Results 701-710 of 19268 for Hemoglobin

1. Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer - Mayo Clinic

   Hemoglobin ≥ 10 g/dL; Creatinine ≤ 1.5 times the upper limit of normal with creatinine clearance ≥ 50 mL/min using the Modified Cockcroft-Gault method ...

2. A Study to Assess the Efficacy and Safety of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II (LAD II) - Mayo Clinic

   duration of the study and 30 days following the last dose of study drug. Exclusion Criteria: - Subject has severe anemia defined as hemoglobin <8.0 g/dL (<4.9 ...

3. Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

   - Hemoglobin >= 9 g/dL or >= 5.6 mmol/L(within 14 days of registration) - Criteria must be met without packed red blood cell (pRBC) transfusion within the ...

4. Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical - Mayo Clinic

   Preoperative hemoglobin <10g/dL; International Normalized Ratio>1.4; Abnormal Partial Thromboplastin Time; Preoperative platelet count of <150,000mm^3 ...

5. Investigational Trial To Evaluate XC001 Delivered Via An Cardiac Catheter In Subjects With Chronic Angina. - Mayo Clinic

   Body mass index \> 45 kg/m2. 5. Hemoglobin \< 10 g/dL, absolute neutrophil count \< 1.2 × 103 per µL, platelet count \< 75,000 per µL, alanine ...

6. Study of Canakinumab in Patients With Myelofibrosis - Mayo Clinic

   - Hemoglobin < 10 g/dL; - Transfusion-dependency (at least 6 units of packed red blood cells (PRBC) in the 12 weeks prior to study enrollment, for a ...

7. Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers - Mayo Clinic

   Absolute neutrophil count (ANC) \< 1.5 x 109/L, hemoglobin \< 10 g/dL, or platelet count \< 100 x 109/L * QT interval corrected by Fridericia's formula ...

8. Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer - Mayo Clinic

   Hemoglobin ≥ 9 g/dL; subjects with hemoglobin ≥ 8-9 g/dL may be included with approval from the Medical Monitor;; In subjects transfused before study entry ...

9. A Study to Evaluate the Effectiveness and Safety of PCS499 in Treating Ulcerations in Patients who have Necrobiosis Lipoidica - Mayo Clinic

   Hemoglobin < 8.0 g/dL (International System of Units (SI): < 80 g/L);; White blood cells < 3.0 x 10^3 cells/mm^3 (SI: < 3.0 x 10^9 cells/L);; Neutrophils ...

10. Metabolic syndrome - Symptoms & causes - Mayo Clinic

    Having three or more specific risk factors, such as high blood pressure or abdominal fat, boosts your risk of type 2 diabetes and heart disease.